 Imara Inc. announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment. The Phase 2a study is testing IMR-687, an oral treatment, in adult patients; so far, a higher dose of the drug has shown a statistically significant increase in F-cells, which have fetal hemoglobin. We know increasing fetal hemoglobin correlates with improved clinical outcomes, Imara CEO Rahul Balla said in a news release. The companys stock has soared 265.8 since it went public in mid-March, making it one of the few companies to file an initial public offering in the U.S. in the weeks leading up to stay-at-home orders as a result of the COVID-19 pandemic. The SP; 500 is up 9.5 over the last three months. 